Ventrus Biosciences

New York, United States Founded: 2005 • Age: 21 yrs
Develops prescription drugs for gastrointestinal disorders
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About Ventrus Biosciences

Ventrus Biosciences is a company based in New York (United States) founded in 2005. Ventrus Biosciences operates in a competitive market with competitors including Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.

  • Headquarter New York, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $2.73 M (USD), Debt – Conventional

    Apr 27, 2010

  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Ventrus Biosciences

Investments & Acquisitions by Ventrus Biosciences

Investments
Premium access

Investment portfolio details for Ventrus Biosciences

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Ventrus Biosciences

Premium access

Detailed financials for Ventrus Biosciences

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Ventrus Biosciences Comparisons

Ventrus Biosciences Primary company
Description
Develops prescription drugs for gastrointestinal disorders
Location
New York, United States
Founded Year
2005
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Ventrus Biosciences

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Ventrus Biosciences

Ventrus Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
Locked Locked Locked
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
Locked Locked Locked
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
Locked Locked Locked
Synbiotics are developed for simulating the gut microbiome.
Locked Locked Locked
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
Locked Locked Locked
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed.
Premium access

Detailed competitors of Ventrus Biosciences

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Ventrus Biosciences

Premium access

Complete news archive for Ventrus Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ventrus Biosciences

Ventrus Biosciences was founded in 2005 and raised its 1st funding round 5 years after it was founded.

Ventrus Biosciences is headquartered in New York, United States. It is registered at New York, New York, United States.

Ventrus BioSciences (formerly known as South Island BioSciences) is a development stage specialty pharmaceutical company, that develops late-stage prescription drugs for gastrointestinal disorders. Pipeline include three late-stage products: Iferanserin ointment (VEN 309) for the topical treatment of hemorrhoids; Diltiazem cream (VEN 307), a topical treatment for the relief of pain associated with anal fissures; and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis (IPAA). In 2014, the company merged with Assembly Pharmaceuticals and Post-merger is known as Assembly Biosciences.

Ventrus Biosciences's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available